News & Updates
Filter by Specialty:
Baricitinib delays, lowers frequency of flares in JIA
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
Negative transrectal ultrasound biopsy tied to low prostate cancer death
Prostate cancer-specific mortality is very low among men with negative transrectal ultrasound (TRUS) biopsies, particularly those with prostate-specific antigen (PSA) <10 ng/ml, reports a study.
Negative transrectal ultrasound biopsy tied to low prostate cancer death
23 Jun 2022
Cardiovascular events complicate condition of sepsis patients
Cardiovascular events (CVEs) pose more problems in half of critically ill patients with sepsis, with nearly four in five developing CVEs within the first week of hospitalization, leading to longer intensive care unit (ICU) and hospital length of stay (LOS), a Singapore study has shown.
Cardiovascular events complicate condition of sepsis patients
23 Jun 2022
Rare gene mutations predict prostate cancer relapse
Rare and deleterious germline mutations affecting inflammatory response and cellular signaling pathways associate strongly with the time to biochemical recurrence (BCR) after radical treatment in patients with prostate cancer (PrCa), according to a recent study.
Rare gene mutations predict prostate cancer relapse
23 Jun 2022
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
23 Jun 2022
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.